Absci (ABSI) to Release Quarterly Earnings on Tuesday

Absci (NASDAQ:ABSI) is expected to issue its Q4 2025 results after the market closes on Tuesday, March 24th. Analysts expect Absci to post earnings of ($0.16) per share and revenue of $1.3810 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

Absci Price Performance

NASDAQ ABSI opened at $2.50 on Tuesday. Absci has a 1 year low of $2.01 and a 1 year high of $5.23. The company has a market capitalization of $375.93 million, a PE ratio of -2.78 and a beta of 2.12. The company has a fifty day moving average of $2.85 and a 200 day moving average of $3.19.

Analyst Ratings Changes

A number of equities analysts have weighed in on ABSI shares. HC Wainwright lifted their price objective on Absci from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a report on Wednesday, January 21st. Morgan Stanley cut Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target for the company. in a research report on Thursday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.00 price target on shares of Absci in a report on Friday, December 12th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Absci has a consensus rating of “Moderate Buy” and a consensus target price of $7.66.

Insider Transactions at Absci

In other news, insider Andreas Busch acquired 100,000 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was acquired at an average price of $2.29 per share, for a total transaction of $229,000.00. Following the completion of the transaction, the insider owned 421,446 shares in the company, valued at approximately $965,111.34. The trade was a 31.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sean Mcclain sold 26,761 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $2.99, for a total value of $80,015.39. Following the sale, the chief executive officer owned 8,334,567 shares in the company, valued at $24,920,355.33. This trade represents a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 10.49% of the company’s stock.

Institutional Trading of Absci

Institutional investors have recently bought and sold shares of the business. Quarry LP purchased a new stake in shares of Absci in the third quarter valued at approximately $26,000. Scientech Research LLC purchased a new position in shares of Absci during the 3rd quarter valued at approximately $31,000. Xponance LLC acquired a new stake in Absci in the 4th quarter valued at $37,000. BNP Paribas Financial Markets grew its stake in Absci by 91.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company’s stock valued at $29,000 after acquiring an additional 5,385 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in Absci by 13,965.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 11,534 shares of the company’s stock worth $35,000 after acquiring an additional 11,452 shares in the last quarter. 52.05% of the stock is owned by institutional investors and hedge funds.

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.